James is a Managing Director at Vertex Holdings and Vertex Ventures HC. James oversees the investment and portfolio management activities at Vertex Ventures HC. Concurrently he leads the Partnership Group at Vertex Holdings, which focuses on facilitating collaborations and building partnerships across the Vertex network.
James serves on the board of directors for Holaira, Palleon Pharma, Bicycle Therapeutics and Kona Medical.
Prior to Vertex, James served as Managing Director at Roots Capital, a fund management company in Singapore; General Manager at Fullerton Credit Services, a China-based financial services firm wholly-owned by Temasek; and a naval officer in the Singapore Armed Forces.
James graduated from Oxford University with a Masters and First Class Honours in Engineering Science.
Mr. Lu, the founder of Biosensors International Group Ltd, was its chairman and CEO from its inception to 2008. He retained his leadership position as chairman of the Group since January 2008 until November 2016.
Mr. Lu has more than 30 years’ experience in the medical industry. Prior to starting Biosensors in 1990, Mr. Lu established Asia-based operations for the Medical Division of Gould Inc in Tokyo in 1978. In 1986, he participated in a management-led leveraged buyout of the division from Gould and he continued as president of the Asia-Pacific division through 1988. Mr. Lu took the company to IPO in Nasdaq and it was subsequently sold to British Oxygen Corporation. He served as president of Asia-Pacific with British Oxygen until 1990.
Mr. Lu is active in both international and local medical arena as an entrepreneurial angel investor. Mr. Lu is a General Partner at Majuven Pte Ltd; Foundry Singapore and a venture partner for medical sector at Vertex Venture Management Pte Ltd. With SPRING, Mr. Lu collaborates with Accuron Technologies Ltd (a wholly- owned subsidiary of Temasek) through the Sector Specific Accelerator program.
Yoh-Chie serves on the board of directors for Earlens, Moximed, Ivantis, Visterra, and Innoventures.
Dr. Carolyn Ng is Principal of Vertex Ventures HC, the venture capital arm of Temasek Holdings specializing in early stage life sciences investments globally. At Vertex, Dr. Ng is responsible for evaluating and driving venture investments across biotechnology, medical devices, and health tech fields. Oncology scientist by background, Dr. Ng is passionate about innovation that impacts patients’ lives. Prior to joining Vertex, Carolyn was a Strategy Consultant at Deallus Consulting, a specialized London-headquartered life sciences consulting firm with clientele comprised of the top 20 global pharmaceutical companies.
Carolyn Ng holds a PhD in Cancer Molecular Biology from the NUS Graduate School for Integrative Sciences and Technology (NGS), where she was a recipient of the prestigious NGS PhD Scholarship. During her academic career, she was a co-inventor of a novel small molecule nuclear receptor activator indicated for the treatment of neuroblastoma. She also holds a BS (Pharmacy) (First Class Honours) degree from the National University of Singapore.
Lori Hu joined the Vertex Ventures HC Palo Alto office in 2015 focusing on global healthcare investments. Prior to Vertex, Lori was an Associate Director for Business Development at Bristol-Myers Squibb, identifying and executing licensing, partnerships and transactions for the Chinese market. She has also worked with SR One, the corporate venture capital arm of GlaxoSmithKline in Boston. Previously, she was a strategy consultant in the health & life sciences practice at Accenture based across Singapore, China and South Africa.
Lori graduated with an MBA from The Wharton School, and MA in International Studies from the University of Pennsylvania where she was a Leonard Lauder Fellow. She also holds a BSE in Biomedical Engineering from Duke University.